327183-32-4

Basic information

• Product Name: Chroman-8-carbaldehyde, 95%
• Synonyms: Chroman-8-carbaldehyde, 95%;3,4-dihydro-2H-chroMene-8-carbaldehyde;chromane-8-carbaldehyde
• CAS NO: 327183-32-4
• Molecular Formula: C₁₀H₁₀O₂
• Molecular Weight: 162.1852
• Mol File: 327183-32-4.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Chroman-8-carbaldehyde, 95%(CAS DataBase Reference)
• NIST Chemistry Reference: Chroman-8-carbaldehyde, 95%(327183-32-4)
• EPA Substance Registry System: Chroman-8-carbaldehyde, 95%(327183-32-4)

Safety Data

• Hazardous Substances Data: 327183-32-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Chroman-8-carbaldehyde, 95% is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its unique structure and properties make it a valuable component in the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
Chroman-8-carbaldehyde, 95% is used as a reagent in organic synthesis for the preparation of heterocyclic compounds. Its versatility in chemical reactions allows for the creation of a wide range of organic compounds with diverse applications.
Used in Dye Production:
Chroman-8-carbaldehyde, 95% is used in the production of dyes due to its ability to impart color to various materials. Its chemical properties make it suitable for use in creating dyes for textiles, plastics, and other industries.
Used in Fragrance and Perfume Industry:
Chroman-8-carbaldehyde, 95% is used in the fragrance and perfume industry for its strong odor and ability to create unique scents. Its incorporation into fragrance formulations can enhance the overall aroma and appeal of perfumes and scented products.

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 206347-33-3 1,3-Dibromo-2-(3-bromo-propoxy)-benzene 
• 493-08-3 chromane 
• 608-33-3 2,6-dibromophenol 
• 1001671-65-3 (2,6-dibromophenyl) (2-chloropropyl) ether 

Downstream Products

• 1037205-45-0 C₂₅H₂₂FN₃O₅S 
• 1037206-64-6 C₂₆H₂₄FN₃O₅S 
• 1037206-59-9 C₂₆H₂₃FN₂O₄ 
• 1037206-62-4 C₂₅H₂₁FN₂O₄ 

Relevant articles and documents

The Key Role of the Nonchelating Conformation of the Benzylidene Ligand on the Formation and Initiation of Hoveyda-Grubbs Metathesis Catalysts

Experimental studies of Hoveyda-Grubbs metathesis catalysts reveal important consequences of substitution at the 6-position of the chelating benzylidene ligand. The structural modification varies conformational preferences of the ligand that affects its exchange due to the interaction of the coordinating site with the ruthenium center. As a consequence, when typical S-chelated systems are formed as kinetic trans-Cl2 products, for 6-substituted benzylidenes the preference is altered toward direct formation of thermodynamic cis-Cl2 isomers. Activity data and reactions with tricyclohexylphosphine (PCy3) support also a similar scenario for O-chelated complexes, which display fast trans-Cl2?cis-Cl2 equilibrium observed by NMR EXSY studies. The presented conformational model reveals that catalysts, which cannot adopt the optimal nonchelating conformation of benzylidene ligand, initiate through a high-energy associative mechanism.

4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS

The present invention relates to 4, 5 - ring annulated indole derivatives of formula ( I ), compositions comprising at leas t one 4, 5 - ring annulated indole derivatives, and methods of using the 4, 5 - ring annulated ^ndole derivatives for treating or preventing a viral inf ection or a virus - related disorder in a patient, (I) wherein ring Z of formula (I), is cyclohexyl, cyclohexenyl, 6-membered heterocycloalkyl, 6- membered heterocycloalkenyl, 6-membered aryl or 6-membered heteroaryl, wherein R1, R2, R3, R6. R7 and R10 are as described herein.

Probing of the ligand anatomy: Effects of the chelating alkoxy ligand modifications on the structure and catalytic activity of ruthenium carbene complexes

Structural modifications of the Hoveyda-Grubbs ruthenium metathesis complex via electronic and structural withdrawing of the chelating alkoxy ligand were investigated. By decreasing the donor properties of the oxygen atom, an acceleration in catalytic act

Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands

A chemical compound of formula (I) wherein R1 and R2 are independently selected from hydrogen and alkyl; R3 is alkyl; R4 and R5 are selected from hydrogen and alkyl; R6 and R7 are independently selected from hydrogen, halogen, hydroxyl, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and A is a 5- or 6-membered ring optionally containing one or more heteroatoms wherein the atoms of the ring A, other than the unsaturated carbon atoms of the phenyl ring to which the ring A is fused, are saturated or unsaturated, and pharmaceutically acceptable salts, addition compounds and prodrugs thereof; and the use thereof in therapy, particularly as an agonist or antagonist of a 5HT receptor, particularly a 5HT2C receptor, for instance in the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.

4,9-ETHANO-BENZO(F)ISOINDOLE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS

Novel products of formula (I): STR1 preparation thereof and pharmaceutical compositions containing said products are disclosed. In formula (I), R is a group of formula (CH 2) m X 1 (CH 2) n Z, where X 1 is a simple bond or O or S, n is 0 or 1 and n is 0,